XOMA has been granted a patent for antibodies targeting transforming growth factor beta (TGFß1, TGFß2, TGFß3). These antibodies are intended for treating various conditions, including cancer and eye diseases, and are characterized by specific amino acid sequences outlined in the claims. GlobalData’s report on XOMA gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on XOMA, NSAID cancer drugs was a key innovation area identified from patents. XOMA's grant share as of July 2024 was 55%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies targeting transforming growth factor beta (tgfß)
The patent US12071475B2 describes a novel antibody that specifically binds to transforming growth factor beta (TGFß) isoforms 1, 2, and 3. The antibody is characterized by specific amino acid sequences for its heavy and light chain complementarity-determining regions (CDRs), as detailed in the claims. It is classified as an IgG2 antibody and can also be modified to include various human antibody framework regions or constant regions. The claims further specify that the antibody may exhibit varying affinities for the TGFß isoforms and can be formulated into sterile pharmaceutical compositions for therapeutic use.
The patent outlines methods for treating a wide range of diseases and conditions associated with TGFß expression, including various cancers, fibrotic diseases, and other disorders affecting multiple organ systems. Specific claims detail the antibody's potential to enhance immune responses by modulating natural killer (NK) cell activity, cytotoxic T cell (CTL) function, and regulatory T cell populations within tumors. The therapeutic applications extend to numerous cancer types, including lung, breast, and prostate cancers, as well as conditions like pulmonary fibrosis and liver cirrhosis. Overall, the patent presents a comprehensive approach to utilizing this antibody in clinical settings for the treatment of TGFß-related diseases.
To know more about GlobalData’s detailed insights on XOMA, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
